Lidocaine metabolite and creatinine measurements in the Ektachem 700: steps to minimize its impact on patient care.

Abstract

Abstract The single-slide method used for creatinine in the Kodak "Ektachem" analyzer is far more precise than the two-slide method. We confirm that sera from patients on intravenous therapy with lidocaine exhibit a positive bias in results for creatinine but that lidocaine itself does not interfere. Instead, N-ethylglycine, a metabolite of lidocaine with a structure similar to that of sarcosine, is probably the cause. A method that allows N-ethyglycine to be measured directly is described. We followed the degree of this interference through five generations of the slide. Our investigations include two detailed comparison studies between the Kodak Ektachem 700 and the Beckman Astra analyzers. Creatinine determinations on lidocaine-treated patients when first-generation slides were used averaged 4.6 mg/L higher than determinations on these same specimens performed in the Astra. Serum creatinine results from patients not on lidocaine showed no significant difference between the two instruments. The average difference in generation 2, 3, and 4 slides was 0.24, 0.22, and 2.5 mg/L, respectively. No more than 2% of our creatinine results had a clinically significant lidocaine-related bias. We show how to identify and correct this small proportion of results that are biased because of lidocaine therapy.